Nicotinamide and Carbogen for Tumor Radiation Response
Author Information
Author(s): D.J. Chaplin, M.R. Horsman, D.W. Siemann
Primary Institution: B.C. Cancer Research Centre
Hypothesis
Can the combination of nicotinamide and carbogen improve the radiation response of hypoxic tumors?
Conclusion
Nicotinamide combined with carbogen breathing can significantly enhance the radiation response of tumors, even at clinically achievable doses.
Supporting Evidence
- Significant radiosensitising effects were observed for all nicotinamide doses tested above 50 mg kg-1.
- Maximal enhancement of radiation response was observed with nicotinamide doses of 250 mg kg-1 or more.
- Combining nicotinamide with carbogen breathing resulted in a cell survival response consistent with a fully aerobic radiation response.
Takeaway
This study found that giving a medicine called nicotinamide along with a special gas can help tumors respond better to radiation treatment.
Methodology
Mice with SCCVII tumors were treated with varying doses of nicotinamide and carbogen breathing times before radiation exposure, and tumor cell survival was measured.
Potential Biases
Potential bias in the selection of tumor models and treatment protocols.
Limitations
The study was conducted in mice, and the applicability to human tumors remains uncertain.
Participant Demographics
6-9 week old female C3H/He mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website